Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: Relief from immunosuppression is associated with clinical response

Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: Relief from immunosuppression is associated with clinical response

Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are innovative small target molecules that, in combination with endocrine therapy, have recently been employed in the treatment of patients with HR+/HER2− metastatic breast cancer (mBC). In this prospective study, we investigate the impact...

Full description

Bibliographic Details
Main Authors: Botticelli, A. (Author), Cortesi, E. (Author), Di Filippo, A. (Author), Marchetti, P. (Author), Napoletano, C. (Author), Nuti, M. (Author), Rughetti, A. (Author), Scagnoli, S. (Author), Scirocchi, F. (Author), Strigari, L. (Author), Tomao, S. (Author), Zizzari, I.G (Author)
Format: Article
Language:English
Published: Elsevier B.V. 2022
Subjects:
CDK4/6i
HR+/HER2- metastatic breast cancer
Immune modulation
MDSCs
Regulatory T cells
Treg
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items